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Killing cancer cells by poly-drug elevation of ceramide levels
A hypothesis whose time has come?
Norman S. Radin
Mental Health Research Institute, University of Michigan, Ann Arbor, MI, USA
Many papers have shown that sphingolipids control the
balance in cells between growth and proliferation, and cell
death by apoptosis. Sphingosine-1-phosphate (Sph1P) and
glucosylceramide (GlcCer) induce proliferation processes,
and ceramide (Cer), a metabolic intermediate between the
two, induces apoptosis. In cancers, the balance seems to
have come undone and it should be possible to kill the cells
by enhancing the processes that lead to ceramide accumu-
lation. The two control systems are intertwined, modulated
by a variety of agents affecting the activities of the enzymes
in Cer-GlcCer-Sph1P interdependence. It is proposed that
successful cancer chemotherapy requires the use of many
agents to elevate ceramide levels adequately. This review
updates current knowledge of sphingolipid metabolism and
some of the evidence showing that ceramide plays a causal
role in apoptosis induction, as well as a chemotherapeutic
agent.
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B A C K G R O U N D
Information about sphingolipids has always occupied a
small space in biochemistry textbooks and their involve-
ment in clinical problems is best known through their
roles in a few rare genetic errors (mainly Gaucher and
Tay-Sachs). However, in the last 10 years or so, a flood of
papers showed a remarkable degree of involvement in
important health issues, such as cancer, viral and bacterial
infections, brain function, the skin barrier, and athero-
sclerosis. Figure 1 shows a summary of sphingolipid
metabolic processes.
The major synthetic enzymes are shown, omitting the
steps by which the sphingols (mainly sphingosine) are
formed. The two phosphate esters are mitogenic but only
the sphingosine ester has received much study [1±3].
Glucosylceramide (GlcCer) is also mitogenic, possibly not
as strongly as the esters but it occurs at a much higher
concentration. It also acts as the precursor of lactosylcer-
amide (GalGlcCer) and a large assortment of more highly
glycosylated glucosphingolipids (GSLs), some of which are
mitogenic while others inhibit proliferation or promote
apoptosis. Among these active GSLs are GalGlcCer and
the sialic acid derivatives, the gangliosides. The effects of
sphingolipid hydrolases can be visualized by imagining that
the arrows in the Figure are reversed. Not shown in this
scheme, are the lyso sphingolipids, such as sphingosylphos-
phorylcholine, which seems to have mitogenic properties.
The reader seeking more basic information about these
reactants should consult sphingolipid review articles [4±7],
which also discuss the many factors relating Cer to
apoptosis.
Ceramide lies in the midst of this cluster of metabolites,
being formed by the de novo route and by hydrolases that
act on the more complex sphingolipids, mainly sphingo-
myelin and GlcCer. Its concentration is reduced by the
actions of a kinase, hydrolases, a glucosyltransferase
(GlcCer synthase), and sphingomyelin synthase. This
multiplicity of anabolic and catabolic enzymes makes it
difficult to identify mechanisms by which Cer and other
agents seem to induce apoptosis, a reagent that should lead
to an increased Cer level may also increase the formation of
counter-apoptotic Cer metabolites.
Not only do the rules of mass action apply, modified by
local Km values, but also dynamic modulation of enzyme
turnover. For example, an increased level of Cer acts to
induce a higher level of GlcCer synthase activity [8±10], so
that measuring the level of Cer in a cell without also
measuring (at least) the levels of GlcCer, sphingomyelin,
and Sph1P can lead to the belief that Cer does not produce
apoptosis. Adding exogenous Cer to cell media may not
induce apoptosis if the cell studied has a naturally high rate
of glucosylation; in fact, this could lead to enhanced
proliferation rather than apoptosis. These obvious relation-
ships are made more complicated by reports that Cer can
accelerate Cer synthesis. In one example of this phenom-
enon, an elevated level of Cer leads to increased
sphingomyelinase activity, which leads to a cycle of
gradually increasing Cer production [11]. The balance
between the pro- and anti-apoptotic growth controllers
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seems to be more critical than the absolute concentration of
any single sphingolipid. The relative concentrations of Cer
and Sph1P have been likened to a `rheostat', determining
whether a cell will tend to die or proliferate [1]. A `see-saw'
or `two-pan balance' would be a more appropriate simile.
This `balance concept' can be stated differently. Apoptosis
can be produced in two ways: by (a) elevating a cell's Cer
concentration or (b) by lowering the concentration of the
sphingolipids that produce proliferation.
The main hypothesis of this paper comes logically from
the above concept: chemotherapy is a multifaceted problem
requiring poly-drug action. An elevated ceramide level can
simply slip out from under the therapist's touch due to the
ability of cells to convert the new ceramide molecules to
neutral (sphingomyelin) and/or anti-apoptotic ceramide
derivatives (Sph1P and GlcCer). Thus the ideal thera-
peutic cocktail should contain inhibitors of: (a) ceramide
glucosylation, (b) ceramide hydrolysis, (c) ceramide
phosphorylation, and (d) sphingosine phosphorylation. In
addition, the cocktail should include stimulators of: (a) de
novo Cer synthesis, (b) sphingomyelin hydrolysis, and (c)
GlcCer hydrolysis. Drugs capable of producing these
actions are already known (Table 1) and most are
commercially available, but only some have been approved
for human use. Curiously, reviews and research reports on
this subject have typically mentioned only one or two of
these pathways, disregarding the fluid dynamics of Cer
metabolism. Drugs able to stimulate the phosphohydrolase
acting on Sph1P [12] or Cer1P might help, but none are
presently known.
While the complexity of the proposed cocktail seems
absurdly high, it should be noted that empirical studies in
cancer patients have shown the value of cocktails made
from as many as five drugs. The reason poly-drug therapy
has not been often used for cancer patients is that there has
been a lack of a strong rationale for choosing specific
drugs. Most of the anti-neoplastic drugs in current use have
been discovered empirically or directed at specific inhibi-
tion of DNA metabolism rather than Cer elevation.
Even researchers studying the anti-neoplastic aspects of
Cer metabolism have been slow to use poly-drug cocktails
of Cer-enhancing drugs, probably because of the satisfying
discovery that many cancer cells in culture have succumbed
to apoptosis with only one drug, or a combination of two
drugs. Few tests of this sort have been carried out in
animals, which obviously pose a much more complex,
Fig. 1.The major synthetic pathways of the simple sphingolipids.
Table 1. Substances that elevate cellular ceramide concentration and produce apoptosis. SM, sphingomyeline; SMase, sphingomyelinase.
Drug or metabolite Effect
Ceramide Produces reactive oxygen, which destroys GSH, which stimulates SM hydrolysis.
Induces faster synthesis of GlcCer. Produces nitric oxide [91].
PDMP, PPPP (`P-drugs') Inhibit transferases that form GlcCer, GalGlcCer, globotriaosylCer, ganglioside GM3,
and 1-O-acyl-N-acetylsphingosine.
N-Butyl deoxynojirimycin Inhibits GlcCer synthase and a-glucosidase-1 (protein glucosidase).
N-Butyl deoxygalactonojirimycin Inhibits GlcCer synthase.
Buthionine sulfoximine Inhibits GSH synthesis, speeding SM hydrolysis and Cer synthesis.
N-Oleoyl ethanolamine Inhibits acid ceramidase and GlcCer synthase, stimulates SMase [58,87].
threo-Sphinganine (Safingol) Inhibits phosphorylation of sphingols.
N,N-Dimethyl sphingosine Inhibits sphingosine kinase.
Phenylacetic acid Lowers GSH, allowing faster SM hydrolysis [92].
Dexamethasone Stimulates SMase [93] but also stimulates GlcCer synthesis and GlcCer hydrolase [94].
Ionizing radiation Produces reactive oxygen, which destroys GSH and speeds SMase [95]. Also activates
ceramide synthase [96].
PSC 833 (Valspodar) Speeds Cer de novo synthesis [8] and SMase [56].
Dietary b-sitosterol Stimulates Cer formation, slows growth, produces apoptosis [97].
Nitric oxide Activates SMases, inhibits neutral and acid ceramidase [98].
d-erythro-2-Tetradecanoylamino-1-phenyl-1-propanol Inhibits neutral/alkaline ceramidase [38].
Arachidonic acid Directly stimulates SM hydrolysis by acid SMase.
Doxorubicin Inhibits GlcCer synthase. Forms ROS, speeding SM hydrolysis.
All-trans retinoic acid and fenretinide Slows GlcCer synthesis [99].
RU486 (mifepristone) Inhibits ceramide glucosylation [74].
Tamoxifen Inhibits GlcCer synthase [100].
Tumor necrosis factor Promotes neutral SMase, ceramide synthase, and acid SMase [101].
D9-tetrahydrocannabinol (THC) Speeds SMase [102].
Daunorubicin Stimulates Cer de novo synthesis and/or SMase [103].
Staurosporine Produces elevated Cer and apoptosis by unknown mechanism [104].
Arabinofuranosylcytosine (Ara-c) Stimulates SMase [105].
Phorbol diester Stimulates de novo synthesis of Cer [106].
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adaptable test subject than a single cell type. Moreover
tumors in humans and mice, once they have been given
time to grow and evolve, are composed of many clonal cell
types, not the (supposedly) single types used in culture
research. The different clones surely differ in their
susceptibility to a particular Cer-enhancing drug.
Cancer cells that are transferred from animal to animal
are given little time to evolve, as researchers normally
return to a frozen primary cell culture after several animal
transfers, in order to maintain the uniqueness of the clone.
Cells implanted into animals for drug testing are thus
unrepresentative and may or may not respond to the one
drug chosen for evaluation. However, cells that have
developed the multidrug-resistance trait (MDR) are
remarkably sensitive to apoptosis induction by Cer-enhan-
cing drugs, especially by Cer glucosylation inhibitors. In
the case of Ehrlich ascites carcinoma cells, which have
been in experimenters' hands for many years, it is likely
that more than one clone is present in many laboratories.
This may explain the partial effectiveness of the inhibitor of
Cer glucosyltransferase, d-threo-1-phenyl-2-decanoyla-
mino-3-morpholino-1-propanol (PDMP), which prevented
cancer cell growth in 30±40% of the mice inoculated with
the cells [13]. The surviving mice did not develop cancer
when they were reinoculated with the cells and had
apparently developed an immune response.
For reasons of economy, one might be tempted to use a
limited poly-drug approach in animal trials, with just a few
Cer-enhancing drugs. While this could yield `promising
results', it would kill only some of the clones present in the
experimental tumor and eventually, in an actual patient,
possibly allowing return of the tumor in the patient.
Additionally, tumors in tissues that are androgen-dependent
will respond better to a Cer-enhancement cocktail if the
cocktail includes anti-androgens. Testosterone stimulates
GlcCer synthesis and inhibits GlcCer glucosidase in murine
kidney [14], so blocking its synthesis and receptors should
prove a useful adjunct for poly-drug therapy of renal cancer.
It is very probable that this approach would be useful also
for prostate and lung cancer.
I S C E R A M I D E S I M P LY A N I R R E L E V A N T
B Y S T A N D E R I N A P O P T O S I S ?
Despite literally hundreds of articles claiming to show an
active role for Cer in apoptosis and many review articles
supporting the claim, some researchers still question the
meaning of these findings. From a clinical viewpoint, this
question is itself somewhat irrelevant, because much
evidence has appeared showing that cells can indeed be
killed, by whatever mechanism, by exposing them to
ceramide or to reagents which are known to increase
ceramide concentration (Table 1). This does not mean that
cells cannot be killed by other means, especially by
metabolites such as caspase-3 that seem to be downstream
from Cer. Conceivably, some cells are killed by one agent
via two modes of action, due to Cer accumulation and some
other action.
Is ceramide formed as the result of apoptosis?
The opinion of some `anti-ceramidists', that the appear-
ance of Cer in cells undergoing apoptosis reflects only a
side-issue, has a basis in the nature of cell death. A dying
cell loses its ATP and thus cannot carry out many synthetic
reactions, yet the hydrolases, which in general do not need
ATP, remain intact for a while. Three hydrolases could
produce ceramide as cells die: GlcCer glucosidase,
sphingomyelinase, and ceramide phosphate phosphatase.
Ceramidase, which would be expected to degrade the
accumulating ceramide, has the ability to synthesize
ceramide from free fatty acids and sphingosine [15]. That
reaction does not require ATP and could be active during
cell death.
Studies have reported the rapid appearance during cell
death of fatty acids (from ester-type phospholipids) and of
ceramide (apparently from its major bound form, sphingo-
myelin). The first of the latter reports was the observation
that decapitation of a mouse or rat and homogenization of
the brain led to rapid ceramide synthesis by neutral, metal-
catalyzed sphingomyelinase [16]. It is interesting that
storage, instead of homogenization of the dissected brain
led to much slower ceramide accumulation, possibly
because sphingomyelin and sphingomyelinase are not
close to each other in intact tissues. There is a certain
possibility that cells undergoing apoptosis in culture (the
system preferred by most researchers) eventually bring the
hydrolases into contact with their sphingolipid substrates,
especially during the usual 24-h incubation time that is
needed to kill many cells. The weakness in the bystander
death argument is that some studies have shown parallel
development of apoptosis and the level of Cer.
The location argument
Another argument of `anti-ceramidists' comes from
consideration of the subcellular localization of sphingoli-
pids and their enzymes. These substances seem to be
localized in several kinds of membranous particles, yet a
careful review of the literature tells us that all the factors
producing elevated Cer levels were found, in specified
cells, to slow cell growth or induce apoptosis or compete
with anti-apoptogenic agents like platelet-derived growth
factor [17], interleukins 10 and 13 [18], or epidermal
growth factor [19]. In addition, the enzymatic reactions that
convert Cer to nonapoptotic (sphingomyelin) or mitogenic
products (GlcCer and Sph1P) have been observed to
prevent apoptosis, as shown by the apoptotic effects of
inhibitors of these enzymes. The `location argument'
assumes that Cer, once formed, may not be able to move
freely between subcellular structures or gain access to the
one site where apoptosis takes place. This belief is based in
part on an unrealistic view of subcellular isolation
techniques, which usually yield visibly heterogeneous
membranes. Significant amounts of undefined membranous
structures are usually discarded.
Intermembranous movement of lipids and other cellular
components is a well established process that includes the
sphingolipids [20,21]. Cer formed de novo in the
endoplasmic reticulum moves to the cytosolic surface of
specific Golgi membranes to be glucosylated. From there,
the GlcCer is either transported to other membranes or
internalized into the interior Golgi surface for further
glycosylation. Some of the Cer has to flip over into the
luminal Golgi surface and convert to sphingomyelin.
Sphingomyelin synthase can also reversibly form Cer and
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lecithin from sphingomyelin and diglyceride. Water-soluble
sphingolipid transport proteins have been isolated and P-
glycoprotein (the multidrug resistance protein) has also
been shown capable of transporting sphingolipids. The
saposins (activators of sphingolipid hydrolases in lyso-
somes) can also transport the lipids. Saposin C, which
activates GlcCer glucosidase and forms Cer, is concentrated
in light mitochondrial, mitochondrial, and microsomal
fractions and (in a nonglycosylated form) in cell nuclei,
suggesting that Cer can be formed in many locations [22].
These transporters may act as membrane `scramblers' or
`flipases.'
Intramembrane movement of lipids can be shown by the
bleaching-diffusion technique, a method that has not been
applied to the Cer-apoptosis question. This kind of
movement occurs with small (possibly homogeneous)
lipid aggregates but the large highly dynamic aggregates
(rafts or caveolae or glycolipid-enriched membrane micro-
domains) may be more fixed. Movement of intracellular
lipids to the outer membrane and lipid-binding agents in the
extracellular fluid is readily demonstrated. The Cer formed
by sphingomyelinase at the cell surface is flipped over to
the cytoplasmic face of the plasma membrane while
phosphatidylserine flips to the external face [23]. This is
a typical step in the apoptotic process. In addition, a
transport protein, NPC1 (Niemann-Pick C protein 1), is
involved in the transfer of cholesterol and sphingolipids
from lysosomes/endosomes and the plasma membrane rafts
that contain caveolin-1 [24]. These rafts also contain much
GlcCer and the acidic GSLs (gangliosides), and much of
the gangliosides that are shed into the extracellular fluid by
tumors originate there [25].
No doubt the rates of release of Cer from the different
sites of synthesis differ, which could explain why different
studies have reported different appearance times, even
multiple waves of appearance. While there is a need for
more details of sphingolipid movement in cells undergoing
apoptosis, the evidence suggesting that they are frozen in
place has to be reevaluated.
The `location argument' has drawn strength from the
uncertainty as to the site where Cer produces apoptosis.
While this uncertainty is not a reason to reject the large
amount of evidence for apoptogenesis by Cer, it is an
important question. Recent research reports suggest that
Cer acts on mitochondria, which is a center of attraction for
apoptosis researchers [26]. Mitochondria are visibly
changed by added Cer or tumor necrosis factor-a. (The
latter substance has often been observed to instigate Cer
production.) Exogenous C6-ceramide induced the formation
of hydrogen peroxide in myeloid leukemia U937 cells [27].
On the basis of specific inhibitor effects, the authors
concluded that reactive oxygen species (ROS), generated at
the ubiquinone site of the mitochondrial respiratory chain,
constitute an early major mediator in ceramide-induced
apoptosis. The involvement of mitochondria was further
indicated by the observation that Cer did not produce
peroxide in cells deficient in mitochondrial respiration.
Adding Cer to JB6 RT101 epidermal tumor cells has
yielded ROS and, as may be predicted, destruction of GSH
[28]. Hydrolysis of sphingomyelin by neutral, Mg21-
dependent sphingomyelinase is under the control of a
cell's oxido/reductase status; i.e. GSH inhibits sphingo-
myelinase [29,30]. This sequence explains the observation
that ceramide added to U937 and HL60 myeloid leukemia
cells and normal skin fibroblasts activated neutral sphingo-
myelinase, producing a further elevation of cellular
ceramide [11]. Both short-chain and long-chain ceramides
produced a large release of ROS and cytochrome c from
mitochondria [31]. However several distinct differences
between the two kinds of Cer were noted with respect to
other electron flow changes.
It is interesting that other GSLs, GlcCer, GalGlcCer, and
gangliosides GD3 and GM1, have been shown to produce
an early burst of peroxide, followed by the mitochondrial
permeability transition and cytochrome c release in isolated
liver mitochondria [32,33]. Sph1P was also found to
destroy GSH in PC12 cells [34], suggesting it is like the
other simple sphingolipids in this respect. These effects
may speed up sphingomyelin hydrolysis [30] and formation
of additional Cer, as part of a homeostasis mechanism
whereby excessive pro-apoptotic sphingolipids increase the
level of Cer and thus steady the balance between
proliferation and apoptosis.
Neutral/alkaline ceramidase has been found to be located
primarily in mitochondria [35]; surely it acts on Cer that
enters or is formed in the mitochondria. The enzyme
probably normally exerts a protective anti-apoptotic effect
in healthy cells. Other studies found ceramide synthase in
mitochondria [36], as well as a high specific activity for
acid ceramidase [37]. Blocking the neutral pH enzyme with
an analog of ceramide, d-erythro-2-tetradecanoylamino-1-
phenyl-1-propanol, produced Cer accumulation in cells and
slowed growth [38].
Ceramide also gave rise to an elevation of a different
form of ROS, nitric oxide, in aortic endothelial cells [39].
Exogenous C2-Cer was taken up by the cell surface
caveolae (a major site for cellular Cer) and this produced
a rise in the endothelial isoform of NO synthase with
subsequent formation of NO. The enzyme was translocated
to an interior site in the cells. Both the H2O2 and NO
produced by Cer act to destroy cellular GSH, which speeds
the hydrolysis of sphingomyelin to form more Cer. This is
another route for cyclic self-augmentation of Cer levels.
Other studies also noted the ability of Cer to produce NO.
Of special interest is the report [40] that short-chain
ceramides not only up-regulated inducible NO synthase but
also increased the level of tumor necrosis factor, a process
in which src-related tyrosine kinases play an important role.
This effect on tumor necrosis factor is the opposite of the
ability of tumor necrosis factor to increase the production of
Cer, making this one more Cer self-augmentation cycle.
The various cycles of this sort probably explain why
apoptosis typically takes many hours to develop: substantial
increases in Cer concentration develop relatively slowly.
The bad-technique argument
While many methods for measuring the level of Cer have
been used in apoptosis research, yielding the conclusion
that Cer induces slowed proliferation and apoptosis, some
doubt was cast on the enzymatic assay method that uses
diglyceride kinase [41]. A new mass spectrometric assay
method was applied to Jurkat T cells that had been treated
with an anti-Fas IgM. While this method of elevating Cer
concentration has been used successfully in other labora-
tories, the mass spectrometric method did not show Cer
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accumulation, although apoptosis was seen. The enzymatic
assay, however, did show an increase. This study, not yet
confirmed in another laboratory, was a major source of
skepticism in a discussion paper [42]. The topic of assay
reliability was discussed further in several letters to Trends
in Biochemical Sciences [43±46]. It is certainly true that
researchers can easily become careless in their use of
analytical methods, especially those involving sphingoli-
pids, and editors should exert their powers to force authors
to certify that they performed some simple validating tests.
The doubt-provoking study [41] did not offer strong
validation of the enzymatic assay, and it suffered by
omission of an important step, the alkaline cleavage of
contaminating diacyl glycerol that competes for the labeled
ATP used in the assay. Further tests are needed to establish
the validity of this source of doubt.
The Farber disease problem
People with genetically defective acid ceramidase (Farber
disease or ceramidosis) accumulate much Cer in their
lysosomes and one could ask why this Cer is not
apoptogenic. The survival of such individuals seems to
indicate that Cer accumulated in lysosomes cannot produce
apoptosis. However examination of patients' cells has
shown that the accumulated Cer induces formation of Mn21
superoxide dismutase, which protects cells against perox-
idative damage [47]. Moreover, examination of Farber
colonocytes showed morphological signs of apoptosis [48].
Ganglioside GD3, a pro-apoptotic GSL that can accumulate
when Cer levels are increased, was found to colocalize with
active caspase-3 in Farber colon tissue. Perhaps part of the
Cer escapes the lysosomes, generating anti-apoptotic and
pro-apoptotic sphingolipids (the `balance' situation described
above). Neutral/alkaline ceramidase must metabolize much
of the escaped Cer. Normally, Cer that is formed in
lysosomes is hydrolyzed and the products are metabolized
further.
A similar consideration applies to studies with Niemann-
Pick patients, who have a low level of acid sphingomye-
linase. In the type C disorder, cholesterol metabolism is
strongly affected and major metabolic patterns are dis-
turbed. Cholesterol binds to sphingomyelin, so changes in
cholesterol levels can activate sphingomyelin conversion to
Cer (shown by removing cholesterol from the cell surface
with lipoprotein-deficient medium).
Other anti-Cer arguments
Other expressions of doubt have suggested that experiments
with short-chain ceramides simply disrupted the physical
structure of the plasma membrane and thus somehow
produced apoptosis in an unnatural way. In the Hofmann/
Dixit letter [45], a study of rabbit platelets treated with Cer
and then thrombin was cited as evidence for membrane
destabilization by Cer. This paper simply reported that C2-
Cer inhibited aggregation and arachidonic acid liberation,
whereas C6-Cer and C8-Cer enhanced these responses [49].
This discovery is a far cry from even a hint of membrane
disruption; apoptosis was not mentioned. The results could
more realistically suggest differences in Cer metabolism
that depend on Cer chain length. Another citation intended
to summon up the destabilization hypothesis was a study of
platelet aggregation in which the uptakes of C2-sphingosine
and C2-sphinganine were compared [50]. Platelet lysis was
obtained with the former Cer (not the saturated Cer) when
added at < 40 mm Cer, a level somewhat higher than those
used in other studies. Because lysis was measured with
platelets that had been prelabeled in vitro with [3H]adenine
instead of by measuring protein release or cell counts, one
can wonder if the lysed cells had the same specific activity
as the unlysed cells. In any event, platelets are very
different from most cells, including cancer cells, because
they are simply cell derivatives of limited complexity.
Still a third citation described the production of apoptosis
by added ceramides, including a natural mixture of long-
chain ceramides [51]. The skeptics [45] were `concerned'
by the finding that the yields of apoptosis were different for
the different chain lengths. It may be noted that long-chain
Cer did enter the neurons despite the use of ethanol as
solvent and the claim [42] that `physiological' Cer does not
enter living cells. Examination of the data in Fig. 1 shows
that the differences were minor, and not statistically
significant. While the question of purely physical effects
of all substances of low polarity on membranes warrants
serious concern, there is a marked lack of supporting
evidence in the case of Cer. The ability of cells to convert
short-chain ceramides to sphingosine and short-chain
GlcCer and sphingo myelin [52] indicates that they behave
like typical substrates rather than simple modifiers of the
physical properties of the plasma membrane (i.e. they are
not simply floating inertly in the plasma membrane; see
also the data later in this paper on the different effects of the
same Cer concentration in different cells).
Some experiments that found apoptosis preceding
noticeable Cer accumulation may point to an independent
mechanism of apoptosis induction but these constitute just a
few pieces of evidence and their significance needs more
study. As discussed above, apoptosis can be produced not
only by Cer elevation but also by a reduction in the anti-
apoptotic sphingolipids such as a stimulation of Sph1P
hydrolysis.
Radford has listed objections to a primary role for Cer in
radiation-induced cell damage, questioning how Cer can
interfere with mitosis after the long delay typical of cell
death after radiation (coming after the early cell death) [53].
Stimulation of Cer synthase in prostate cancer cells in vitro
and in vivo with phorbol diester improved the response to
radiation, raising the level of Cer and inducing early
apoptosis [54]. It is possible that Cer levels can rise slowly
by any of several cyclic self-amplification processes, based
on the ability of Cer to generate H2O2 and nitric oxide and
stimulate sphingomyelinase, described above in this paper.
Surely the radiolytic damage to cells, which quickly yields
ROS and GSH destruction, can be expected to yield Cer
elevation and apoptosis [27,54]. Early destruction of cancer
cells by radiation seems to owe much to this process, while
delayed death of cancer cells may well owe much to a
variety of radiolytic processes, including damage to DNA
and agents of mitosis.
A systematic examination of the criteria needed to
demonstrate apoptosis induction by ceramide follows
below.
q FEBS 2001 Killing cancer cells by increasing ceramide level (Eur. J. Biochem. 268) 197
C R I T E R I O N ( A ) : E X O G E N O U S
C E R A M I D E S H O U L D P R O D U C E
A P O P T O S I S
Well over 100 studies have reported that adding ceramide to
cells in culture almost always results in apoptosis and/or
growth inhibition. A few studies have found that exogenous
ceramide stimulates growth and, in some cases, this was
traced to conversion to sphingosine or Sph1P.
Almost all studies with exogenous Cer have utilized a
short-chain ceramide, C2-, C6-, or C8-Cer made from
sphingosine. Virtually all have yielded apoptotic effects or
slowing of growth, except with MDR cells, which
glucosylate (detoxify) the Cer very rapidly. The short-
chain ceramides are used because they seem to dissolve in
cell media and enter cells readily. However, it is likely that
C6-and C8-ceramides precipitate as a fine suspension when
their solution in organic solvent is added to the media.
Researchers do not usually measure the percentage of
added Cer that is actually absorbed by the cells.
These short-chain ceramides are typically active at
inducing apoptosis at a concentration of 3±30 mm in the
cell medium. We do not know how much of the absorbed
Cer reaches `the' site of apoptosis. This situation has
seemed to some investigators to indicate a pharmacological
effect rather than a `natural' effect. To repeat the comment
above: this does not rule out the therapeutic value of
exogenous or endogenous Cer. The use of apoptotic agents
other than ceramides has led to increases in Cer content of
as much as 20-fold. This implies that Cer metabolism is or
can be remarkably active. A study with long-chain
ceramides, the much more typical ones containing C16 to
C26 fatty acids, has shown much higher potency. Using a
different solvent for these ceramides, dodecane/ethanol, Ji
et al. [55] showed that apoptosis could be produced by as
little as 25 nm ceramide. This is an impressive difference,
supporting the conclusion that the common ceramides can
be remarkably deadly to cells if they are in the right
location. As dodecane is also insoluble in incubation media,
it probably precipitates out in cell media together with the
Cer in the form of very small droplets that fuse with the
plasma membrane. Only a few other studies have been
reported with this solvent. Unfortunately for the use of
solvents that form Cer suspensions on dilution with media,
the size of the particles and their ability to access cells may
be very sensitive to variation in laboratory technique.
Moreover the rate of uptake of the long-chain ceramides
may be so slow in some cells that diversion to other
products may dominate the apoptotic effect. There is a need
to use true solubilizers (cyclodextrin derivatives, lipid
transport proteins, or serum albumin) or suitable liposomal
dispersions.
C R I T E R I O N ( B ) : E N D O G E N O U S LY
F O R M E D C E R A M I D E S H O U L D A L S O
I N D U C E A P O P T O S I S
Many techniques are available for apoptosis production by
elevating Cer levels in cancer cells, but only the major ones
are mentioned in Table 1. Most of the agents in the table
produced apoptosis in susceptible cells, but in some
publications, resistant cells were also reported or a second
Cer-elevating agent was needed for apoptosis. This is the
result of the balance problem: cells differ in the importance
of any particular enzyme involved in Cer metabolism.
These differences in susceptibility weaken the claims that
Cer effects are due to nonspecific physical effects on
plasma cell membranes.
The reader may be surprised to note that the table
includes commercial drugs in current or proposed use for
cancer chemotherapy, but this is to be expected if Cer
accumulation is a practical therapeutic approach.
C R I T E R I O N ( C ) : U S E O F T W O
C E R A M I D E - E L E V A T I N G D R U G S
S H O U L D P R O D U C E A P O P T O S I S M O R E
R E A D I L Y T H A N E I T H E R O N E A L O N E
This kind of finding strengthens the proposal that cancer
cells could be killed more readily by use of several Cer-
elevating drugs. Here is a short list of studies in which two
modalities proved more effective than one.
(a) The KB-3-1 cell line succumbed to the apoptotic
action of PSC 833 (valspodar), which was shown to act by
greatly increasing the ceramide content of cells [8].
Inclusion of a common anti-neoplastic agent, vinblastine
(which also causes increases in ceramide), resulted in even
greater ceramide accumulation and loss of viability.
(b) With KG1a leukemia cells, which apparently make
ceramide relatively slowly, treatment with tumor necrosis
factor-a did not generate Cer or apoptosis [56]. However
combination with PSC 833 increased the Cer concentration
and neutral sphingomyelinase activity, and produced
apoptosis. PSC 833 alone led to a threefold increase in
inner plasma membrane sphingomyelin content and neutral
sphingomyelinase activity.
(c) MCF-7-AdrR cells, which are resistant to the toxic
action of doxorubicin and have a high level of GlcCer
synthase activity (characteristics of MDR cells), were found
to be insensitive to C6-ceramide as well as to tamoxifen (an
inhibitor of Cer glucosylation). However, a mixture of the
two reduced cell viability to 42% and elicited apoptosis
[57].
(d) N-Oleoyl ethanolamine, which blocks acid cerami-
dase and should cause accumulation of Cer, did not produce
apoptosis in cultured sensory neurons from neonatal mice.
(In general, normal cells seem to be somewhat less affected
by Cer-elevating drugs than cancer cells.) Exogenous long-
chain Cer, without the inhibitor, increased survival, even in
the absence of nerve growth factor in the medium.
However, the combination of the two produced apoptosis
[51]. The anti-apoptotic action of Cer alone was apparently
due to rapid hydrolysis to sphingosine, which may have
been converted to Sph1P. A similar study with the
ethanolamine amide, which reported that the inhibitor
blocks ceramide glucosylation, found that the amide
potentiated apoptosis induced by C6-ceramide [58].
(e) C6-Ceramide was found to produce apoptosis in CHP-
100 neuroepithelioma cells, an effect that was markedly
potentiated by PDMP, a potent inhibitor of ceramide
glucosylation [59]. At the concentration of PDMP used
here, there was no effect on cell viability when adminis-
tered alone.
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C R I T E R I O N ( D ) : C E R A M I D E S H O U L D
R E A C T W I T H E N Z Y M E S A N D P R O T E I N S
If Cer is simply an ash from the fire of apoptosis, one would
not expect it to show direct activity on enzymes, but it does
in fact stimulate two enzymes that regulate apoptosis and
cell growth, protein phosphatase-1 and protein phospha-
tase-2A [60]. The stimulation was accomplished with long-
chain Cer and cell-free enzymes. Prolonged incubation of
3T3 cells with PDMP, which forces accumulation of
ceramide, led to the production of three phosphorylated
proteins [61].
Ceramide has also been shown to act directly on several
enzymes, activating a protein kinase (CAPK), a guanine-
nucleotide exchange factor (Vav), and protein kinase C zeta
(j). At a concentration as low as 0.1 mm, C8-Cer was found
to rapidly stimulate the phosphorylation of epidermal
growth factor receptor [62].
Ceramide derived from neutral sphingomyelinase activa-
tion is thought to be involved in modulating MAP kinases,
phospholipase A2 (arachidonic acid mobilization), and
ceramide-activated protein phosphatase (CAPP), while
ceramide generated through acid sphingomyelinase activa-
tion appears to be primarily involved in NF-kB activation.
Cer resulting from the lysosomal acidic sphingomyelinase
regulates phosphatidylinositol 3-kinase, which plays a role
in the balance between apoptotic and anti-apoptotic lipids
[18]. Other downstream targets for ceramide action include
COX, interleukin-6 and interleukin-2 gene expression,
retinoblastoma protein, c-Myc, c-Fos, c-Jun and other
transcriptional regulators.
In one study, ceramide was found to bind specifically to
two other protein kinase C isoenzymes, the alpha and delta
forms, but not to the epsilon or zeta forms [63]. This was
shown with a photoaffinity analogue of Cer. The alpha form
increased in activity as the result of the combination. A
similar situation exists regarding the formation of a
complex between ceramide and the endosomal acidic
aspartate protease, cathepsin D [64]. The binding resulted
in formation of enzymatically active cathepsin D.
These effects suggest that ceramide is a metabolite with a
wide repertoire of actions rather than an inert product of
decay.
C R I T E R I O N ( E ) : A C T I V E C E R A M I D E
S H O U L D H A V E A S P E C I F I C C H E M I C A L
S T R U C T U R E
Studies comparing ceramides or Cer-like substances have
shown that apoptosis almost always requires ceramides that
exhibit the d-erythro structure and the trans double bond
typical of sphingosine (i.e. acyl sphinganine is usually
found to be inactive). Researchers who add sphingolipids
containing sphinganine should keep a factor in mind: while
a desaturase can act on the saturated ceramide, the
desaturation is not instantaneous. However the short-chain
ceramides apparently cannot be desaturated [65]. It is true,
as Hofmann and Dixit have proposed [45], that even slight
differences in structure also affect the physical properties of
the ceramides, but these seem like second-order phenomena.
The double bond in active ceramides is in the allylic
position, which renders the hydroxyl at C3 quite chemically
reactive and sensitive to oxidation. It is not surprising that
such ceramides are involved in oxido/reduction reactions
(see above). The quinone group in mitochondrial ubiqui-
none [27] may well oxidize unsaturated Cer or form a
condensation product with it. A miniature version of the
allylic region in sphingosine derivatives, (S)-3-hydroxy-4-
pentenoic acid, stereospecifically undergoes oxidation in
mitochondria, where the allylic ketone condenses with GSH
to form a thio ether and potentiates cell death [66]. The
hydroxy acid does not attack cytosolic GSH and one might
guess the same is true for Cer. Thus it appears that only a
small portion of cellular Cer is involved in apoptosis via
mitochondrial damage.
Hofmann and Dixit, in their critique of the Cer apop-
togenesis hypothesis [42], noted that Liu et al. [30] had
found that oxidized GSH (GSSG) was also a sphingomye-
linase inhibitor. From this, they concluded that the redox
state of the cell is unlikely to affect sphingomyelinase
action. However there are multiple redox levels within cells
and the ROS produced by Cer converts GSH and GSSG to
products containing S-linked oxygen and S-linked NO [39].
GSSG is of little relevance as it occurs at a much lower
concentration than GSH [30]. ROS, particularly nitrogen-
containing ROS, oxidize other cellular sulfur compounds,
which explains the manifold effects of increases in Cer.
Under the topic of structural specificity, we should
appreciate that several studies have found distinct differ-
ences in behavior between short-chain and long-chain
ceramides, and between purely aliphatic ceramides and
ceramides containing a fluorescent moiety. While fluores-
cence is a useful property, interpretation of the results of
such sphingolipid experiments should be made cautiously.
C R I T E R I O N ( F ) : T H E F O R M A T I O N
O F C E R A M I D E O U G H T T O B E
A C C O M P A N I E D B Y L O S S O F A
C E R A M I D E P R E C U R S O R
In some studies showing accumulation of Cer as the result
of stimulating sphingomyelinase, researchers have also
reported loss of sphingomyelin, making it likely that the
Cer was indeed formed by one or more SMases. In fact, the
suggestion was offered that the loss of sphingomyelin was
the cause of apoptosis. In most studies with an inhibitor of
Cer glucosylation, GlcCer was found to disappear and Cer
was found to increase, with production of apoptosis. In this
case, the apoptosis was the result of two changes: the
disappearance of a growth stimulator (GlcCer) and the
appearance of the pro-apoptotic factor, Cer. In the pro-
duction of apoptosis by stimulation of de novo sphingol
biosynthesis, one ought to be able to demonstrate a decrease
in the levels of serine and palmitic acid. In the stimulation of
sphingol acylation, one ought to detect a lower level of
sphingols and long-chain acyl-CoA.
Such `coordinate assays' act to validate the experi-
menter's analytical method for determining Cer changes.
T H E H Y P E R S E N S I T I V I T Y O F
M U LT I D R U G R E S I S T A N T C E L L S
T O B L O C K A D E O F C E R A M I D E
G L U C O S Y L A T I O N
This hypersensitivity was first reported in 1994 in a study of
PDMP effects [67]. Two strains of CHO cells were
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compared to an MDR strain of CHO cells, which makes
much multidrug-resistance protein, P-gp. Incubation in
5 mm dl-PDMP for 5 days completely blocked the growth
of the MDR cells while producing little or no effect on two
other cell types. The latter required 30 or 50 mm PDMP to
block growth completely, a typical effect seen in a wide
variety of cancer cells.
A more detailed demonstration of the importance of the
glucosylation pathway was shown in the laboratory of
M. Cabot. This group found that MDR cells have a far
higher activity of GlcCer synthase and content of GlcCer
than the `wild-type' parental cells [68,69]. Two additional
GSLs, probably GalGlcCer and globotriaosylCer, were also
greatly elevated. Incorporation of [3H]palmitate into the
GlcCer was < eight times faster in the MDR cells,
suggesting that ceramide and sphingol synthesis was also
much faster. Patients exhibiting high GlcCer levels in their
tumors failed conventional chemotherapy [69], showing the
relevance of this MDR aspect. These are very important
points that distinguish normal tissue from MDR tumors
and make the latter sensitive to control by Cer elevation
therapy.
An additional test of the connection was made by
transfecting GlcCer synthase into wild-type (parental)
breast cancer cells [70]. Selected clones, activated with
doxycycline, exhibited up to an 11-fold increase in the
activity of GlcCer synthase and high resistance to apoptotic
damage by doxorubicin (a common test for MDR). The
transfected cells also became resistant to the toxic action of
exogenous ceramide, unlike the parental cells. Evidently, as
the authors concluded, this was due to rapid conversion of
the added ceramide to GlcCer in the MDR cells. The
parental cells, which did not glucosylate their Cer rapidly,
were readily killed by exogenous Cer. A similar comparison
with P388 leukemia cells and an MDR variant strain
showed that C6-Cer was somewhat more toxic to the
parental strain [71]. Note that this difference in response to
Cer by the two kinds of cancer cells is unlikely to support
the belief that Cer uptake experiments give artefactual
results. It was possible to block the resistance to
doxorubicin damage by transfecting the MDR cells with
an antisense polynucleotide active against ceramide gluco-
sylation [72]. In other words, the MDR effect was induced
simply by specifically raising the ability of the cells to
accumulate GlcCer and removed by simply slowing GlcCer
synthesis.
The same sensitivity to Cer accumulation was seen with
the glucosyltransferase inhibitor, 1-phenyl-2-palmitoyla-
mino-3-pyrrolidino-1-propanol (PPPP), and a group of
KB carcinoma cell lines [73]. Here, the inhibitor produced
marked apoptosis and decreased viability in the MDR cell
lines, as well as loss of poly(ADP-ribose) polymerase
(PARP). The PARP cleavage was quite visible even within
2 h. Direct addition of ceramide to MDR and parental cells
showed the same kind of difference [74].
The important conclusion to draw from these studies is
that the most aggressive type of cancer cell, the MDR cell,
is very sensitive to apoptosis from its rapidly forming
endogenous ceramide, provided that its diversion to
mitogenic sphingolipids is blocked. Including a stimulator
of Cer synthesis, like PSC 833, should augment the
treatment. These are encouraging findings for patients
who no longer respond to the usual treatments.
The high concentration of P-gp in MDR tumors may
simply be an inductive response to the rapid production of
GSLs which apparently have to be brought to the cell
surface and expelled into the extracellular fluid by P-gp
[20]. Thus P-gp may be responsible for GSL shedding by
tumors [75] and its activity in expelling absorbed anti-
cancer drugs is simply an accidental byproduct of the
phenomenon. The dependence of P-gp on GSL levels was
shown in neuroblastoma cells treated with dl-PDMP, which
gradually leads to loss of cellular GSLs [76]. The GSL-
depleted cells demonstrated slower ejection of labeled taxol
and vincristine, which the authors attributed to a possible
combination between the PDMP and P-gp (and/or multi-
drug resistance protein). However it is possible that the
lowered concentration of GSLs led to a lower level of the
transport proteins. Other evidence in this study, inciden-
tally, suggested that taxol itself also inhibits GlcCer
synthesis, which may account for its anti-neoplastic
activity. Similar evidence for the ability of GSLs to
promote drug resistance was obtained with colchicine-
adapted colon carcinoma cells, which accumulated a
different drug-resisting protein, MRP1, plus Cer, GlcCer,
and GalCer [77].
T H E P R O L I F E R A T I V E E F F E C T S
O F G L U C O S Y L C E R A M I D E
A C C U M U L A T I O N
A major theme in this paper is the importance of the
balance between pro- and anti-apoptotic sphingolipids in
which GlcCer plays a major role. While considerable
evidence for this role has appeared, it is little known and
warrants elaboration here. The first indication that GlcCer
promotes cell proliferation and growth came from the
observation that Gaucher disease patients gradually develop
a greatly enlarged spleen and liver. These patients produce a
defective, mutated form of GlcCer glucosidase, which is not
active enough to prevent accumulation of GlcCer. Treating
the patients with a modified form of b-glucosidase stops the
accumulation, slowly eliminates stored GlcCer, and tends to
normalize the enlarged organs.
An animal model of Gaucher disease was created by
injecting a large amount of GlcCer, which became
concentrated in the liver, producing a liver weight increase
of < 25% within 25 h [78]. The liver growth included
increases in total protein, DNA, total lipids, thymidine
kinase, and ornithine decarboxylase, all suggestive of a
normal mitogenic reaction to the absorbed GlcCer. The
extra liver disappeared fairly soon as the (normal) GlcCer
glucosidase cleaved the GSL, showing considerable
dependence on the lipid for the normal size of the organ.
Cultured cells also grow faster when exposed to
inhibitors of GlcCer glucosidase (conduritol B epoxide
and N-hexyl-glucosylsphingosine), which force GlcCer
accumulation [79,80]. The same has been found in mice
that were injected eight days with the epoxide: the brains
were 13% heavier and the livers were 9% heavier [81]. The
number of cells growing freely in the abdomen of mice
inoculated with Ehrlich ascites carcinoma cells increased
50% after five daily injections of GlcCer [13]. As one
would predict, inhibition of GlcCer synthesis blocks the
growth of all cells tested, further supporting the role of
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GSLs in proliferation. This use of glucosylation inhibitors
looks promising for abnormally enlarged tissues [82].
Several kinds of experiments demonstrated the important
role of GalGlcCer in promoting proliferation of the
epithelial cells lining arteries [83]. Additional kinds of
evidence for glucosphingolipids as stimulators of cell
growth have been reviewed [84,85].
I N T E R P R E T I N G E X P E R I M E N T S W I T H
E N Z Y M E I N H I B I T O R S
The literature on Cer apoptogenesis contains many
examples of the use of inhibitors to explain the mechanism
producing Cer accumulation and apoptosis. Unfortunately,
most of these studies have made the simplistic assumption
that the observed changes were due to simply slowing the
enzymatic step. Little thought has been given to the concept
that inhibiting an enzyme leads to depletion of the normal
enzyme products' products due to normal catabolism of
those products (e.g. PDMP causes not only depletion of
GlcCer but also of the higher GSLs). In addition, there can
be accumulation of the enzyme's substrates and diversion
of these precursors to other bioactive products. A common
example is the use of fumonisin B1, which blocks sphingol
acylation and should therefore produce loss of Cer,
stimulate growth, and prevent apoptosis. However, studies
of this inhibitor, a significant public health problem because
of its frequent contamination of cora, have shown that
sphinganine and sphingosine accumulate. These com-
pounds are active as producers of growth inhibition and
stimulation, possibly undergoing faster phosphorylation to
form sphingol phosphates. In the case of Swiss 3T3
fibroblasts, DNA synthesis was stimulated by the inhibitor
[86]. Ketosphinganine, the intermediate in sphinganine
biosynthesis, was found to undergo acylation with stearoyl
CoA to form a keto Cer [37]. If fumonisin blocks this
acylation too, it may well produce accumulation of the keto
sphingol, a reactive sphingolipid which could be respon-
sible for some of fumonisin's toxic effects.
Interpreting experiments using inhibitors is also fraught
with the danger of inadequate knowledge of the reactions
blocked by the inhibitor. For example, N-oleoyl ethanola-
mine is generally considered to inhibit only ceramidase, but
inhibition of GlcCer synthesis has been reported [58]. In
addition, exposing WEHI-231 cells to the amide activated
neutral sphingomyelinase, thus elevating Cer production
and ROS [87]. It also induced mitochondrial permeability,
cytochrome c release, and apoptosis.
PDMP, which is usually described as an inhibitor of
ceramide glucosylation, has also been found to inhibit
galactosylation of GlcCer, sialylation of GalGlcCer, synth-
esis of globotriaosyl Cer, the enzymes that synthesize and
hydrolyze 1-O-acyl C2-ceramide, and the endoglycosidase
that cleaves GSLs. However most of these actions simply
block Cer consumption and cause loss of GSLs.
The concentration of inhibitor is an additional variable,
since the different inhibitory effects depend on the different
Ki values. At low concentrations of PDMP and a similar
drug, PPPP, ceramide glucosylation was rather effective,
but at higher concentrations Cer was found to accumulate,
with consequent growth inhibition or apoptosis [88]. It is
clear that ambiguity can result from failure to use more than
one kind of inhibitor and analyze for more than a few
sphingolipids.
W H A T I S T O B E D O N E N E X T ?
There is a clear need to analyze cells or tissues (normal and
cancerous) for more than a few sphingolipids, and to use
more than one kind of inhibitor, if one is to deduce a
reasonably unambiguous interpretation of experiments on
apoptosis or proliferation. The same applies to comparisons
of different cell types, such as parental and MDR cells.
Assays for different sphingolipid enzymes should be
included. Science grows by making strong deductions, but
experimenters must furnish strong data.
There is an urgent need to move to animal cancer
experiments with poly-drug mixtures that can elevate Cer
levels and lower the levels of anti-apoptotic sphingolipids.
Once success is obtained with monoclonal tumor inocula-
tions, tests should be run with more natural tumors
consisting of complex, evolved clonal mixtures. MDR
tumors, the most aggressive kind of tumors, should be
examined for sensitivity to Cer poly-drug therapy. The use
of immunologically impaired mice should be avoided as
much as possible, since Cer poly-drug therapy can be
expected to improve anti-tumor immunological responses
[75,89]. Surviving animals should be tested for the
formation of an immune response, by (at the minimum)
reinoculating them with the same cancer cells.
Future studies of Cer uptake should more often use long-
chain ceramides complexed with a truly water-soluble
carrier, preferably a mixture of lipid-transport proteins.
Future use of Cer glucosylation inhibition should utilize the
newer, much more potent analogs of PDMP [90]. An
intensive effort should be devoted to synthesizing and
testing new drugs that might be more effective inhibitors or
stimulators of Cer synthesis. Many `lead' compounds are
available (Table 1) as guides for the design. The com-
pounds should be tested not only in specific sphingolipid
enzyme assays, but also in intact cells that have been
incubated with the test drug, as some drugs induce enzyme
changes indirectly.
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